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Abstract
Purpose This study aimed to explore differences in physical
activity and fitness between women with metastatic breast
cancer compared to healthy controls and factors associated
with their physical activity levels.
Methods Seventy-one women with metastatic breast cancer,
aged (mean (SD)) 57.7 (9.5) and 2.9 (3.1)years after the onset
of metastatic disease, and 71 healthy controls aged 55.0 (9.4)
years participated. Of those with metastatic disease, 27 % had
bone-only metastases, 35 % visceral-only metastases and
38% bone and visceral metastases. Patient-reported outcomes
and physical measures of muscle strength and aerobic fitness
assessments were obtained. Participants wore a SenseWear®
physical activity monitor over 7 days, and the average steps/
day and the time spent in moderate-to-vigorous intensity
physical activity were determined.
Results Women with metastases were significantly (i) less
aerobically fit than the control group (25.3 (5.4) vs. 31.9
(6.1)mL•kg−1•min−1; P<0.001); (ii) weaker (e.g. lower limb
strength for the metastatic and control groups was 53.5 (23.7)
vs. 76.0 (27.4)kg, respectively; P<0.001); (iii) less active,
with the metastatic group attaining only 56 % of the mean
daily step counts of the healthy women; and (iv) more symp-
tomatic, reporting higher levels of fatigue and dyspnoea
(P<0.001).
Conclusion Women living in the community with metastatic
breast cancer possessed lower aerobic fitness, reduced mus-
cular strength and less daily physical activity compared to
healthy counterparts. They also experienced poorer function-
ing and higher symptom burden.
Implications for Cancer Survivors Women living with meta-
static breast cancer may benefit from a physical activity pro-
gramme to address their physical impairments.
Keywords Physical activity . Fitness . Strength .Metastatic
breast cancer
Introduction
In 2012, there were approximately 14,680 new breast cancers
diagnosed and 2,940 breast cancer-related deaths in Australia.
For women, the risk of developing breast cancer before the
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age of 85 is one in eight [1]. Approximately 7 % of breast
cancer cases will present as metastatic disease, and a further
10 % will develop metastases within 5 years of an early breast
cancer diagnosis [2]. For these women, the 5-year relative
survival is 41 % [3]. With advances in treatment significantly
improving prognosis, identifying opportunities to optimise
function and well-being has become increasingly important.
Although many women live long productive lives with
metastatic breast cancer, there are numerous complex medical,
social and emotional challenges that are present. Declines in
quality of life and disease-related symptoms have been ob-
served [4–6]. However, the physical status of this population
remains unclear. For example, habitual physical activity levels
in individuals with metastatic disease have not been previous-
ly described.
Women with metastatic cancer may be open to the idea of
undertaking increased daily physical activity or structured
exercise to improve their physical and psychosocial well-
being. For instance, a cross-sectional study of community-
dwelling palliative care patients reported that >90 % were
interested in participating in a physical activity programme
[7]. However, consideration is required to identify what bar-
riers to greater activity participation may exist as well as the
impact of their physical impairments. Barriers to participation
in physical activity have not been explored in women living
with metastatic breast cancer; however, it has been explored in
a large cross-sectional study of persons treated for cancer, with
stages ranging from I to IV. The five most common barriers
that interfered with exercise participation were illness, joint
stiffness, fatigue, pain and lack of motivation [8]. Physical
impairments have been documented in womenwithmetastatic
breast cancer, with 92 % of the population reporting to have at
least one physical impairment and almost 50 % a limitation in
muscle strength [9]. Such existing impairments coupled with
multidimensional barriers may impact on one’s ability to carry
out physical activity.
Physical activity promotion has become a focus of cancer
rehabilitation therapy and research. Its effect on treatment-
related side effects and quality of life in women with early
stage breast cancer has been extensively documented [10–12].
Conversely, women with metastatic breast cancer have tradi-
tionally been excluded from physical activity interventions
due to fear of pathological bone fracture and cancer-related
fatigue, which is a persistent, subjective sense of tiredness
related to cancer or cancer treatment that interferes with usual
functioning [12–14]. However, a number of pilot and case
series studies suggest that this group may experience appre-
ciable physical and psychosocial benefits from increased
levels of physical activity, including reduced fatigue, lower
symptoms of dyspnoea and improved physical function [15,
16]. In order to deliver an appropriately designed exercise
programme, it is necessary to understand the current physical
capabilities of this population.
The aims of this study were therefore to determine the level
of physical activity, fitness and patient-reported outcomes in
women with metastatic breast cancer compared to similarly
aged healthy controls as well as to explore the medical,
demographic, patient-reported outcome and physical factors
associated with physical activity.
Methods
Participants
Two groups of women were recruited: (i) women with meta-
static breast cancer (n=71) and (ii) women with no history of
cancer (n=71). Women with metastatic disease were recruited
from the outpatient departments of six metropolitan cancer
centres in Sydney. Eighty-one women were invited to partic-
ipate in the study by their oncologist or breast nurse during a
routine clinic visit. Women were eligible if they had been
diagnosed with metastatic breast cancer and were able to
communicate in English and in whom the oncologist expected
survival of at least 6 months. Participants also had to be living
in the community and ambulatory, as defined by an Eastern
Cooperative Oncology Group (ECOG) performance status of
0–3 [17].
Women with no history of cancer were recruited through
internal advertising at The University of Sydney and via
Register4, an online community for breast cancer research
volunteers in Australia.Womenwere eligible if they had never
had cancer, were living in the community and ambulatory and
were able to communicate in English.
Participants in both groups were screened for cardiovascu-
lar, neurological and musculoskeletal risk factors using the
Physical Activity Readiness Questionnaire (PAR-Q) [18].
Participants in whom medical evaluation was indicated
discussed the study in detail with their oncologist or primary
care physician to gain medical clearance (Physical Activity
Readiness Medical Examination (PARmed-X) [18]) prior to
enrolling in the study.
The study was approved by the Human Research Ethics
Committee at each of the institutions where women were
recruited, and all participants provided written informed
consent.
Protocol
Assessments were undertaken in the participant’s home or at
another convenient location. Background information includ-
ing medical history and medications was recorded.
Measurements of stature, body mass, muscular strength, aer-
obic fitness and daily physical activity were obtained. As field
tests of physical fitness have not been validated in women
with metastatic breast cancer, tests validated in similarly aged
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populations were selected. Patient-reported outcomes (PROs)
were obtained from self-report questionnaires. A standardised
protocol was implemented whereby participants were asked to
rest for 10–15 min between the various physical assessments.
Following these measurements, the participant wore a
SenseWear® physical activity monitor for 1 week.
Participants were instructed to maintain their usual activities
throughout the monitoring period.
Measurements
Physical activity assessment Physical activity level was
determined from the Godin Leisure-Time Exercise
Questionnaire (GLTEQ) [19] and from a physical activity
monitor. The GLTEQ is a robust measure used to quantify
physical activity [20, 19] and is commonly used to assess
physical activity in cancer patients [21–23]. It is a simple
measure that uses self-recall to quantify the frequency of
vigorous, moderate and light-intensity physical activities
performed for more than 15 min at a time, during a typical
week. These frequencies were computed to give a total
leisure time activity score.
Participants were asked to wear a SenseWear® arm-
band (BodyMedia, Inc., Pittsburgh, PA, USA) [24–26] for
all waking hours, except during water-based activities, for
a period of seven consecutive days. The SenseWear® is a
physical activity monitor worn over the triceps brachii
muscle of the arm and is designed to capture typical
activities of daily life including standing, sitting, walking,
running and cycling. The device continuously samples
physiological parameters including heat flux, galvanic
skin response, skin temperature and near-body ambient
temperature and includes a two-axis accelerometer. Data
from these sensors are combined with gender, age, body
mass and stature to estimate daily energy expenditure and
amount of physical activity performed (SenseWear®
Professional Software, version 7.0, BodyMedia, Inc.,
Pittsburgh, PA, USA). The SenseWear® has been shown
to be highly reliable [27] and valid for use in healthy
adults, with intraclass correlations of 0.80 to a gold stan-
dard for energy expenditure [26, 24]. Variables calculated
from the SenseWear® include the time spent in moderate-
to-vigorous intensity physical activity (MVPA) and steps
taken per day (steps/day). The time spent in MVPA was
determined using a criterion threshold ≥3 METs [28].
Fitness assessment Aerobic fitness was estimated using the
Modified Canadian Aerobic Fitness Test (mCAFT) [29–31].
Participants were required to complete one or more 3-min
stages of stepping up and down on a two-step bench.
Following completion of each stepping session, heart rate
was recorded using a heart rate monitor (FT4, Polar Electro
Oy, Finland). If a participant did not reach the desired heart
rate, the participant proceeded to the next, more demanding
stepping stage. Sessions continued until the participant’s heart
rate exceeded 85 % of age-predicted maximal heart rate. The
stepping cadence and duration of each exercise stage was
regulated using music provided with the mCAFT protocol.
Aerobic fitness was reported as maximal oxygen consumption
(VO2max), predicted frommCAFTequations which have been
validated in a healthy adult population [29]. VO2max for each
participant was then compared to population normative values
[32].
Handgrip strength was measured using hand dynamometry
(Jamar Plus+; Sammons Preston Rolyon, Bolingbrook, IL,
USA) [33]. Hand dynamometry has been shown to have
excellent test-retest reliability in many studies, with intraclass
correlation coefficient values ranging between 0.81 and 0.98
[34–36]. With the participant standing with feet hip distance
apart, toes pointing forward and eyes looking straight ahead,
participants grasped the dynamometer between the fingers and
the palm at the base of the thumb. The dynamometer was held
in line with the forearm at the level of the thigh with the arm
slightly abducted so that it is not touching the body [31]. The
participants were instructed to squeeze the handgrip as force-
fully as possible to generate maximal force, performing at
least three trials on each hand. The maximal absolute handgrip
strength (handgrip strengthABS) of the dominant limb was
used for analysis.
Lower limb strength was measured using a back-leg
dynamometer (Back-D; Takei Kiki Kogyo, Tokyo, Japan)
[37]. Information on the reliability of such dynamometers
is limited; however, one study observed significant cor-
relation coefficients (r=0.80) when examining test and
retest measures [37]. Participants stood on the footplate,
with the scapulae and buttocks positioned flat against a
wall. Participants flexed the legs until the knee extension
angle was between 130° and 140° and then reached down
with elbows fully extended. The pull bar of the dyna-
mometer was placed in the hands, and the chain length
was adjusted. Participants were instructed to extend the
legs with maximal effort, pulling the bar simultaneously.
At least three trials were performed, and the highest
absolute score used to determine leg strengthABS.
Relative handgrip and leg strength was determined by
dividing handgrip strengthABS and leg strengthABS by
the participant’s body mass to derive handgrip
strengthREL and leg strengthREL to account for partici-
pants of different statures [38].
Patient-reported outcomes The 30-item European
Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC QLQ-30) [39, 40] was used,
whereby items relating to five dimensions of functioning are
rated: physical, role, social, emotional and cognitive. In addi-
tion, a range of items relating to symptoms are rated: fatigue,
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nausea and vomiting, pain, dyspnoea, insomnia, appetite loss,
constipation and diarrhoea. This questionnaire has been used
extensively in cancer patients with reliabilities ranging from
0.69 to 0.90 across the various dimensions and symptoms. A
higher score for a functional scale represents better well-
being, whereas a higher score for a symptom scale represents
a higher burden of symptomatology. For analysis, function
scales and symptoms were considered independently.
The Functional Assessment of Chronic Illness Therapy:
Fatigue (FACIT-F) was used to assess the severity and impact
of fatigue [41, 42]. The FACIT-F was originally designed to
measure cancer fatigue and is commonly used in this popula-
tion [43, 44]. The maximum score is 52, with a lower score
indicative of more significant fatigue.
The Life-Space Assessment (LSA) was used to assess
mobility based on the distance a person reports moving during
the preceding 4-week period [45–47]. The LSA has demon-
strated to have excellent test-retest reliability with an intraclass
coefficient of 0.96 [45]. Questions establish movement to
specific life spaces ranging from within one’s home to beyond
one’s town. Specific levels are assessed by asking: “During
the past 4 weeks, have you been to other rooms of your home
besides the room where you sleep; to an area outside your
home such as your porch, deck or patio, hallway of an apart-
ment building, or garage; to places in your neighborhood,
other than your own yard or apartment building; to places
outside your neighborhood but within your town; and to
places outside your town?” For each level, participants are
asked how many days within a week they attained that level
and whether they required help from equipment or another
person. The scores for this questionnaire range from 0 to 120,
with a higher score representative of a higher pattern of
mobility.
Statistical analyses Independent t tests were used to assess
differences between the metastatic and healthy groups on
continuous variables. These comparisons were repeated
using regression modelling that adjusted for age and body
mass index (BMI) as part of a sensitivity analysis.
Multiple regression was used to determine if any of the
demographic, fitness or PRO variables (as reported in
Table 2) were related to MVPA and steps/day.
Candidates for inclusion in each initial multivariate model
comprised those variables that attained P<0.25 on univar-
iate analysis. A backward elimination approach from each
initial model was used to progressively eliminate covari-
ates that were not statistically significant at the 0.05 level.
Variables were tested for collinearity, and only non-related
variables were retained. Adequacy of the final model was
assessed by examination of residuals. Means and standard
deviations are presented unless otherwise stated.
Statistical analyses were performed using IBM SPSS
Version 20 for Windows (IBM Corp. Somers, NY, USA).
Results
Women with metastatic disease aged 57.7 (9.5)years, and
healthy controls aged 55.0 (9.4)years. The BMI of the meta-
static group was 27.3 (5.9) vs. 25.0 (4.4)kg•m−2 for the
healthy group. Of those with breast cancer, the median and
interquartile range for time since metastatic disease onset was
1.5 years (1.0 to 4.0 years; Table 1). Twenty-seven women
had metastases to both bone and viscera (38 %), 25 to viscera
only (35 %) and 19 to bone only (27 %). Forty-nine percent of
women were receiving chemotherapy and 45 % receiving
hormone therapy.
All women in the healthy group completed the physical
assessments; however, not all of the metastatic group was
able to do so. Of the 71 women with metastatic cancer, 53
(i.e. 75 %) completed all physical components of the
study. Eight completed only PROs and physical activity
monitoring, being unable to complete fitness testing for a
variety of reasons, including living too far from the test-
ing sites (n=3), undiagnosed hypertension (n=2), dys-
pnoea (n=2) and neuropathy (n=1). The remaining wom-
en (n=10) were able to complete either strength or aerobic
testing, but not both. Reasons for being unable to com-
plete both components included disease or treatment-
Table 1 Medical characteristics of the metastatic cancer group
n=71
Time since primary BC diagnosis (years; mean (SD)) 7.8 (5.5)
Time since MET diagnosis (years; mean (SD)) 2.9 (3.1)








Location of metastasis (%)
Bone only 27
Visceral only 35











BC breast cancer, MET metastatic breast cancer
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related factors such as severe lymphoedema (n=1) and
biomechanical limitations as a result of hip or knee re-
placements (n=3). Other reasons included restrictions ex-
pected in an older population such as arthritic pain (n=2),
balance concerns (n=1) and cardiac issues (n=3).
Notably, no adverse events occurred in those who were
able to complete the assessments.
Levels of physical activity
The women with metastatic cancer were significantly less
active, attaining only 56 % of steps/day (5,434 (3,174) vs.
9,635 (3,327) steps/day, P<0.001) of their healthy counter-
parts (Fig. 1). The metastatic group also spent a significantly
lower duration engaged in MVPA (82 (78) vs. 142 (82)min,
respectively, <0.001).
Levels of aerobic fitness and muscle strength
Women with metastatic disease had a significantly lower
estimated VO2max than the healthy women (Fig. 1; 25.3
(5.4) vs. 31.9 (6.1)mL•kg−1•min−1, P<0.001). More healthy
women had a predicted VO2max value above average for their
age, based on population normative values, compared to the
metastatic group (81 vs. 37 %, P<0.001). In addition, the
metastatic group was also significantly weaker with respect
to absolute and relative strength measures. Leg strengthABS
for the metastatic and healthy groups was 53.5 (23.7) vs. 76.0
(27.4)kg (P<0.001), and leg strengthREL was 0.76 (0.31) vs.
1.15 (0.45)kg •kg−1, respectively (P<0.001). Handgrip
strengthABS was 26.6 (6.0) vs. 30.2 (6.4)kg (P=0.001), and
handgrip strengthREL was 0.38 (0.09) vs. 0.46 (0.11)kg•kg
−1,
respectively (P<0.001). Further analysis revealed that these

































































































































Fig. 1 Comparison of the
metastatic group with the healthy
group on physical activity and
fitness measures. Mean and
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Patient-reported outcomes
FACIT-F demonstrated that fatigue was significantly higher in
women with metastatic cancer compared to their healthy
counterparts (38.0 (9.8) vs. 46.3 (4.6), P<0.001) (Table 2).
Women with metastatic disease scored lower in all functional
domains of the EORTC QLQ-30 (P<0.001) and were also
more symptomatic, reporting higher levels of nausea, pain,
dyspnoea, appetite loss, constipation and diarrhoea (P<0.05).
The between-group comparisons of physical activity, fitness
and PROs did not change significantly when adjusting for age
and BMI.
Relationships with physical activity
Table 3 reveals the variables that were predictors of physical
activity, with no strong evidence that having metastatic dis-
ease alters these associations. Handgrip and leg strengthREL,
VO2max, body mass and BMI were significantly related to
MVPA (P<0.001). A number of fitness indicators and PROs
were related to steps/day, including handgrip and leg
strengthREL, VO2max, FACIT-F, appetite loss and physical
function (P<0.05).
Steps/day were significantly related to physical function,
pain, age, BMI, VO2max and leg strengthREL. This regression
Table 2 Comparison of demo-
graphics, physical measures and
patient-reported outcomes be-
tween women living with meta-
static breast cancer and healthy
women
ABS absolute, REL relative
aMissing data for the following
variables (number of cases miss-
ing): VO2max (17), handgrip
strength (10), leg strength (11)
and steps and MVPA (6)
bMVPA refers to minutes spent in
moderate-to-vigorous intensity







difference (95 % CI)
P
Age (years) 57.7 (9.5) 55.0 (9.4) −2.7 (−5.8 to 0.4) 0.091
Height (m) 1.63 (0.07) 1.64 (0.06) 0.01 (−0.02 to 0.03) 0.605
Body mass (kg) 72.7 (16.9) 67.1 (12.5) −5.6 (−10.5 to −0.7) 0.027
BMI (kg•m−2) 27.3 (5.9) 25.0 (4.4) −2.3 (−4.0 to −0.5) 0.010
Physical fitness
VO2max (mL•kg
−1•min−1) 25.3 (5.4) 31.9 (6.1) 6.6 (4.5 to 8.7) <0.001
Handgrip strengthABS (kg) 26.6 (6.0) 30.2 (6.4) 3.6 (1.4 to 5.8) 0.001
Handgrip strengthREL
(kg•kg−1)
0.38 (0.09) 0.46 (0.11) 0.08 (0.04 to 1.11) <0.001
Leg strengthABS (kg) 53.5 (23.7) 76.0 (27.4) 22.5 (13.6 to 31.4) <0.001
Leg strengthREL (kg•kg
−1) 0.76 (0.31) 1.15 (0.45) 0.39 (0.26 to 0.53) <0.001
Physical activity
Steps/day 5434 (3174) 9635 (3327) 4200 (3088 to 5313) <0.001
MVPAb 82 (78) 142 (82) 63 (36 to 91) <0.001
GLTEQ 23.6 (20.6) 54.1 (30.7) 30.5 (21.9 to 39.2) <0.001
Life-Space Assessment 77.2 (23.0) 90.1 (13.5) 12.9 (6.6 to 19.2) <0.001
FACIT-F 38.0 (9.8) 46.3 (4.6) 8.3 (5.8 to 10.8) <0.001
EORTC QLQ-30
Function scales
Global health 70.8 (20.4) 81.7 (15.0) 10.9 (5.0 to 16.9) <0.001
Physical 78.4 (17.4) 95.0 (8.5) 16.6 (12.1 to 21.2) <0.001
Role 79.8 (23.7) 95.5 (10.1) 15.7 (9.6 to 21.8) <0.001
Emotional 78.5 (19.9) 85.9 (12.4) 7.4 (1.9 to 12.9) 0.009
Cognitive 84.3 (15.1) 91.1 (11.2) 6.8 (2.4 to 11.2) 0.003
Social 75.1 (24.9) 96.5 (8.9) 21.4 (15.1 to 27.6) <0.001
Symptoms
Fatigue 31.3 (21.0) 14.4 (11.9) −16.9 (−22.6 to −11.2) <0.001
Nausea/vomiting 6.8 (14.2) 1.2 (5.9) −5.6 (−9.3 to −2.0) 0.002
Pain 18.5 (23.0) 11.0 (18.9) −7.5 (−14.5 to −0.5) 0.035
Dyspnoea 21.6 (25.3) 4.7 (13.0) −16.9 (−23.6 to −10.2) <0.001
Insomnia 26.8 (30.7) 21.1 (24.7) −5.6 (−14.9 to 3.6) 0.230
Appetite loss 12.7 (22.1) 2.3 (10.3) −10.3 (−16.1 to −4.6) 0.001
Constipation 18.3 (25.7) 1.9 (12.5) −16.4 (−23.2 to −9.7) <0.001
Diarrhoea 8.0 (16.4) 2.8 (10.9) −5.2 (−9.8 to −0.5) 0.029
Financial difficulties 26.8 (30.7) 21.1 (24.7) −5.6 (−14.9 to 3.6) 0.230
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model explained 42 % of the variance (P<0.001). MVPAwas
significantly related to body mass and handgrip strengthREL,
explaining 45 % (P<0.001) of the variance. Notably, having
metastatic disease did not explain either of these models. For
both of these models, some data were missing for a variety of
reasons, as outlined above, so these findings should be
interpreted with some caution.
Discussion
The aim of this study was to develop an understanding of the
physical activity and fitness of women with metastatic breast
cancer. Women with metastatic disease, whilst overall of
lower fitness than a similarly aged healthy cohort, were able
to participate in this study. Interestingly, some women with
metastatic disease exceeded the fitness and walking capacity
of women without cancer, indicating a wide range of physical
abilities.
As expected, the metastatic group displayed significantly
decreased aerobic fitness and strength compared to the healthy
group. Aerobic fitness in the metastatic group was, on aver-
age, 21 % lower than healthy controls. Notably, when aerobic
fitness was presented as age-adjusted normative scores [32],
many in the metastatic group outperformed their healthy
peers, including 21 women who exceeded the average fitness
band for their age. Furthermore, all women with metastatic
disease who were able to undergo aerobic fitness assessment
demonstrated VO2max values greater than that required for
Table 3 Association of the com-
bined group’s demographics,
physical measures and patient-re-
ported outcomes with steps/day
and MVPA
MVPA refers to moderate-to-vig-
orous intensity physical activity
(≥3 METS)
ABS absolute, REL relative
MVPA Steps/day
β 95 % CI P β 95 % CI P
Age (years) −0.4 −1.9 to 1 0.553 −41.8 −101.8 to 18.2 0.171
BMI (kg•m−2) −7.8 −10.1 to −5.5 <0.001 −74.0 −181 to 32.9 0.173
Body mass (kg) −2.6 −3.4 to −1.8 <0.001 −25.8 −63.2 to 11.5 0.174
Fitness measures
VO2max (mL•kg
−1•min−1) 6.0 3.5 to 8.5 <0.001 210.1 110.3 to 309.8 <0.001
Fitness percentile 1.3 0.8 to 1.8 <0.001 40.6 19 to 62.1 <0.001
Handgrip strengthABS (kg) 1.9 −0.4 to 4.3 0.108 63.2 −29.5 to 155.9 0.180
Handgrip strengthREL
(kg•kg−1)
465.0 347.1 to 582.8 <0.001 6945.4 1369.8 to 12520.9 0.015
Leg strengthABS (kg) 0.3 −0.3 to 0.9 0.320 27.1 4.9 to 49.2 0.017
Leg strengthREL (kg•kg
−1) 75.6 39.7 to 111.5 <0.001 2207.8 761.7 to 3653.9 0.003
GLTEQ 0.7 0.2 to 1.2 0.010 51.6 32.4 to 70.8 <0.001
Life-Space Assessment 0.5 −0.2 to 1.2 0.174 35.2 5.8 to 64.6 0.019
FACIT-F 1.1 −0.8 to 2.9 0.258 138.3 67.1 to 209.5 <0.001
EORTC QLQ-30
Function scales
Global 0.6 −0.2 to 1.3 0.152 32.3 0.9 to 63.7 0.044
Physical 0.4 −0.6 to 1.5 0.411 73.9 34.3 to 113.5 <0.001
Role 0.4 −0.4 to 1.2 0.315 47.9 17.8 to 77.9 0.002
Emotional 0.4 −0.4 to 1.2 0.329 21.8 −11.9 to 55.5 0.202
Cognitive −0.7 −1.7 to 0.4 0.199 6.1 −36.2 to 48.3 0.777
Social 0.3 −0.6 to 1.1 0.504 43.9 10.9 to 76.9 0.010
Symptoms
Fatigue −0.5 −1.4 to 0.3 0.206 −60.5 −92.4 to −28.5 <0.001
Nausea/vomiting −0.8 −2.1 to 0.5 0.228 −51.8 −104.8 to 1.2 0.055
Pain 0.0 −0.6 to 0.7 0.953 −13.7 −40.7 to 13.3 0.319
Dyspnoea −0.2 −0.9 to 0.5 0.518 −21.0 −48.7 to 6.6 0.134
Insomnia 0.1 −0.4 to 0.6 0.737 −13.9 −33.9 to 6.1 0.171
Appetite loss 0.0 −0.8 to 0.9 0.952 −47.6 −82 to −13.1 0.007
Constipation 0.3 −0.4 to 1 0.414 −2.9 −32.8 to 27 0.848
Diarrhoea −0.4 −1.3 to 0.6 0.470 −38.4 −77.8 to 1 0.056
Financial difficulties 0.1 −0.4 to 0.6 0.737 −13.9 −33.9 to 6.1 0.171
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functional independence, i.e. 15 mL•kg−1•min−1 [48, 49].
These findings suggest that limitations to participation in
aerobic type activities are not a consequence of reduced aer-
obic fitness. For those unable to perform activities of daily
living, other factors such as pain, fatigue, comorbidities and
strength need to be considered.
Previous research reported that women with metastatic
breast cancer possess aerobic fitness, on average, 33 % less
than that of healthy sedentary women [23], larger than the
21 % difference in this study. Possible explanations for this
discrepancy may include the use of a sub-maximal, home-
based, aerobic step test in this study. Although the mCAFT
has been validated [29], the risk of under- or overestimating
VO2max increases as compared to completing a maximal aer-
obic assessment in a laboratory [23]. Another possible expla-
nation is a response bias in participant selection. All women
recruited to the aforementioned study [23] were receiving
some form of cytotoxic chemotherapy. However, in the cur-
rent study, only 49 % of women were undergoing
chemotherapy.
Not surprisingly, our findings revealed that the metastatic
group also experienced significantly lower functioning across
all domains and higher symptomatology when compared to
their healthy peers. It has been suggested that interventions
designed to address clusters of symptoms, such as the combi-
nation of fatigue, nausea, decreased appetite and dyspnoea [6],
may bemore efficacious than those targeting individual symp-
toms. To date, the role of physical activity to address this
symptom cluster has not been explored. However, as fatigue,
in particular, is reduced with increased physical activity [50],
the role of regular exercise is worth exploring.
Despite presenting with poor quality of life, the metasta-
tic group in this study reported higher functioning and less
symptomatology compared to other studies of women living
with metastatic cancer [51, 23]. This may be explained by
the potential difference in participant characteristics and
treatment regimens in such a heterogeneous population.
For example, a large percentage of our cohort has metasta-
ses confined to bone, for which median survival is longer
compared to those with visceral disease. This more indolent
disease course is often treated with less aggressive treat-
ment, and patients generally have fewer symptoms [52].
The level of function demonstrated by this cohort of women
with metastatic disease was surprising, particularly that
many were above average fitness of women without cancer
of the same age. In addition, many women presented with
mild or no symptoms related to their cancer. For this cohort
of women, symptoms and physical capacity may be less of a
barrier to being physically active compared to the general
metastatic breast cancer population.
The metastatic group was significantly more sedentary,
achieving only 56 % of steps/day and 58 % of MVPA com-
pared to the healthy group (Fig. 1). Several fitness indicators
and symptoms were associated with physical activity, al-
though there was no strong evidence that having metastatic
disease contributed significantly. When the healthy and met-
astatic groups were combined, a range of outcomes including
higher levels of physical function, aerobic fitness and leg
strengthREL, low levels of pain, low BMI and being younger
explained higher daily step counts. MVPA was associated
with low body mass and increased handgrip strengthREL. In
neither model of physical activity did having metastatic dis-
ease contribute significantly. This reiterates that these women
with metastatic cancer, whilst deconditioned, did not appear to
be significantly debilitated by their disease.
The physical limitations experienced by women with met-
astatic disease could potentially be improved through physical
activity programmes. Those who were least active demon-
strated low levels of aerobic fitness and strength. A pro-
gramme incorporating both of these aspects could address
these underlying impairments. As persons with metastatic
cancer have historically been encouraged to rest, there have
been few investigations into the impact of structured exercise
or lifestyle physical activity interventions in this population.
Whilst minimal evidence is currently available, pilot interven-
tions suggest that physical activity has the capacity to decel-
erate the decline in physical performance in metastatic cancer
patients, with the potential to improve or maintain mobility
and independence in daily life [15, 16]. Research examining
physical activity preferences in patients with metastatic dis-
ease found that 84 % of patients would be interested in a
programme that could be conducted at home and that 72 %
reported walking as their preference [7]. As such, a starting
point for this population might be the implementation of a
walking programme. In our cohort, the median steps/day were
4,655, with only 15% achieving >8,000 steps/day, the level at
which most health benefits are achieved in older populations
[53]. However, as physical activity levels vary extensively in
this population, a patient-specific approach with
individualised guidance is recommended. Whether structured
exercise programmes or lifestyle physical activity interven-
tions are more clinically efficacious for health and quality of
life in this population is currently unclear.
Although this study has many strengths, there were also a
few limitations. It is likely that women in this study were
functioning higher as compared to the average metastatic
population. With its focus on physical activity, it is possible
that there was a response bias in both groups whereby those
with a particular interest in their personal fitness, higher phys-
ical abilities or a keenness to participate volunteered for the
study. For practical purposes, robust field measures were used
to assess physical fitness in both groups in place of gold
standard laboratory measures. Another limitation relates to
the potential underestimation of physical activity due to activ-
ities not captured via the SenseWear® armband, such as
cycling or swimming.
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In summary, individuals with metastatic breast cancer pos-
sessed reduced aerobic fitness, lower strength and more sed-
entary physical activity levels compared with age-matched
healthy controls. They also experienced poorer functioning
and higher symptom burden. Although those with metastatic
cancer experienced such deficits, the population examined in
this study was still capable of functioning independently and
should be encouraged to be physically active. Whilst struc-
tured exercise and lifestyle physical activity interventions
have previously focused on women with early stage breast
cancer, this research identifies a need to investigate the poten-
tial benefits for women living with metastatic disease.
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